Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

CSI Presents Three-Year Orbit I Coronary Data at CRT 2013



  CSI Presents Three-Year Orbit I Coronary Data at CRT 2013

Results Demonstrate CSI’s Technology Safely Treats Calcified Coronary Arteries

  * Orbital atherectomy treatment using CSI’s system led to a 97 percent
    procedural success rate
  * Study shows low event rates up to three years post procedure

Business Wire

ST. PAUL, Minn. & WASHINGTON -- February 25, 2013

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today presented three-year
data from its ORBIT I feasibility study of calcified coronary lesions during a
poster session at the 2013 Cardiovascular Research Technologies (CRT)
conference.

The ORBIT I study evaluated the safety of CSI’s orbital atherectomy system as
a treatment for mild to severely calcified coronary arteries. Results from the
50-patient feasibility trial formed the basis for the ORBIT II pivotal trial.
This three year feasibility data shows that using CSI’s technology to treat
calcified coronary arteries before stenting achieved not only early procedural
success but also positive long-term outcomes.

“This case series demonstrates that CSI’s system can safely modify calcified
lesions and facilitate stent delivery in this subset of difficult-to-treat
patients,” said presenter Dr. Stevan Himmelstein, Baptist Memorial
Hospital-Desoto, Memphis, Tenn. “Coronary artery disease, or CAD, is the
leading cause of death for men and women in the United States. To have a
potential solution for this pressing problem is encouraging.”

It is estimated that moderate to severe arterial calcium is present in nearly
40 percent of patients treated with interventional therapies. Calcium can lead
to poor outcomes and higher treatment costs in coronary intervention when
traditional therapies are used, including a significantly higher occurrence of
death and major adverse coronary events.

The ORBIT I study consisted of 50 patients enrolled at two sites in India from
May to June 2008. All subjects had at least one calcified coronary lesion with
stenosis between 50 and 100 percent. 33 of the 50 patients were enrolled at
one of the two sites and were followed for three years post procedure. The
evaluated safety endpoint was major adverse cardiac event (MACE) rates.

Results show:

                                                                      
             In            1 month       6 months      2 years       3 years
             hospital      post          post          post          post
             %             procedure     procedure     procedure     procedure
                           %             %             %             %
Overall      6.1           9.1           12.1          15.2          18.2
MACE
Cardiac      0             0             3.0           6.1           9.1
death
Non
Q-Wave       6.1           9.1           9.1*          9.1           9.1
MI
Q-Wave       0             0             0             0             0
MI
TLR          0             3.0           3.0*          3.0           3.0
* One non Q-wave MI at 30 days that led to TLR
 

David L. Martin, CSI president and chief executive officer, said, “Based on
the results from our ORBIT I clinical study, demonstrating the safety in
treating severely calcified coronary lesions our orbital platform technology
may be well suited for the removal of calcified plaque in coronary arteries.
Our pivotal 443-patient ORBIT II PMA clinical study has recently concluded and
we are nearing completion of an FDA submission to secure a coronary indication
for our technology.”

CSI completed enrollment in the ORBIT II trial in November of 2012. ORBIT II
is CSI’s pivotal coronary IDE trial studying this problematic subset of
patients. CSI is targeting the end of this quarter to submit its Premarket
Approval (PMA) package to the FDA.

CSI Booth at CRT: Feb. 25 – 26

Visit CSI at booth #112, 8 a.m. – 5 p.m. today and 9 a.m. – 2 p.m. Tuesday,
Feb. 26, to meet the company’s calcium experts and learn more about CSI’s
unique orbital technology.

About Coronary Artery Disease
Coronary Artery Disease (CAD) is a life-threatening condition and leading
cause of death in men and women in the United States. CAD occurs when a fatty
material called plaque builds up on the walls of arteries that supply blood to
the heart. The plaque buildup causes the arteries to harden and narrow
(atherosclerosis), reducing blood flow. The risk of CAD increases if a person
has one or several of the following: high blood pressure, abnormal cholesterol
levels, diabetes, or family history of early heart disease. CAD affects an
estimated 16.8 million people in the United States and is the most common form
of heart disease. Heart disease claims more than 600,000 lives, or 1 in 4
Americans, in the United States each year.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of the
Diamondback Orbital Atherectomy System in August 2007. To date, over 100,000
of CSI’s devices have been sold to leading institutions across the United
States. CSI has also commenced its ORBIT II Investigational Device Exemption
clinical trial to evaluate the safety and effectiveness of its orbital
technology in treating coronary arteries. The coronary system is limited by
federal law to investigational use and is currently not commercially available
in the United States.

For more information, visit the company’s website at www.csi360.com.

Product Disclosure
The Stealth 360°^® PAD System, Diamondback 360^® PAD System and Predator 360^®
PAD System are percutaneous orbital atherectomy systems indicated for use as
therapy in patients with occlusive atherosclerotic disease in peripheral
arteries and stenotic material from artificial arteriovenous dialysis
fistulae. The systems are contraindicated for use in coronary arteries, bypass
grafts, stents or where thrombus or dissections are present. Although the
incidence of adverse events is rare, potential events that can occur with
atherectomy include: pain, hypotension, CVA/TIA, death, dissection,
perforation, distal embolization, thrombus formation, hematuria, abrupt or
acute vessel closure, or arterial spasm.

Contact:

Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
Sarah Wozniak, 651-259-1636
swozniak@csi360.com
or
Padilla Speer Beardsley Inc.
Marian Briggs, 612-455-1742
mbriggs@padillaspeer.com
or
Dave Folkens, 612-455-1741
dfolkens@padillaspeer.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement